phenylalanine has been researched along with Metabolic Syndrome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolanowski, M; Daroszewski, J; Gamian, A; Mierzchała-Pasierb, M; Rybka, J; Siomkajło, M; Stankiewicz-Olczyk, J | 1 |
| Bales, CW; Bethel, MA; Califf, RM; Davies, MJ; Haffner, SM; Holman, RR; Huffman, KM; Kraus, WE; McMurray, JJ; Sun, JL; Thomas, L; Tuomilehto, J; Yates, T | 1 |
| Economopoulos, KP; Gharedaghi, MH; Gul, SS; Hamarneh, SR; Hamilton, AR; Hodin, RA; Hu, D; Huo, H; Hyoju, SK; Liu, W; Morrison, S; Munoz, AR; Phupitakphol, T; Zhang, W | 1 |
| Hirose, T; Kudo, K | 1 |
| Hirose, T | 1 |
2 review(s) available for phenylalanine and Metabolic Syndrome
| Article | Year |
|---|---|
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2011 |
[Sulfonylureas and glinides].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Nateglinide; Phenylalanine; Sulfonylurea Compounds | 2006 |
3 other study(ies) available for phenylalanine and Metabolic Syndrome
| Article | Year |
|---|---|
Specific plasma amino acid disturbances associated with metabolic syndrome.
Topics: Adult; Amino Acids; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Anthropometry; Biomarkers; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; Phenylalanine; Reproducibility of Results | 2017 |
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
Topics: Aged; Cyclohexanes; Diet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Motor Activity; Nateglinide; Phenylalanine; Placebos; Tetrazoles; Valine; Valsartan | 2014 |
Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice.
Topics: Alkaline Phosphatase; Animals; Aspartame; Biomarkers; Biotransformation; Blood Glucose; Diet, High-Fat; Enzyme Inhibitors; Glucose Intolerance; Insulin Resistance; Intestinal Mucosa; Intestine, Small; Male; Metabolic Syndrome; Mice, Inbred C57BL; Non-Nutritive Sweeteners; Obesity; Phenylalanine; Tumor Necrosis Factor-alpha; Weight Gain | 2017 |